Clinical Research Directory

Inclusion Criteria: * Men and women aged over 18 * Patients with Hidradenitis suppurativa (Hurley stages II-III) * Disease affecting at least two distinct anatomical areas, * Total count of abscesses (A) and inflammatory nodules (N) ≥ 3 * IHS4 score ≥ 11 * Treatment of pain with opioids (≥ 20 mg/day) * Resistance to previous use (for at least 3 months) of systemic antibiotics and TNF inhibitors (infliximab or adalimumab) or anti-IL17 (secukinumab). * Vaccinations against SARS-CoV-2 and influenza up to date (or able to be carried out prior to the study procedure) * Women using an effective method of contraception * Signed informed consent Exclusion Criteria: * Active viral infection: herpes, VZV, HIV, HBV, HCV * Active bacterial infection requiring systemic antibiotics * Known allergy to blood components/plasma proteins * Poor myocardial function (increased risk of for transfusion-associated circulatory overload) (symptomatic left ventricular failure and ejection fraction \< 40%) * Pregnant women * Subjects with no social security coverage